Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (noted as Insight Molecular Diagnostics Inc. in metadata) on February 16, 2016. The filing addresses corporate governance and management changes, specifically the grant of stock options to executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation details.
- Option Grant Price: $3.06 per share
- Option Expiration: 10 years from the date of grant
Material Changes
On February 16, 2016, the Board of Directors granted stock options to three executive officers under the Employee Stock Option Plan. This represents a new compensatory arrangement rather than a change in financial performance.
| Executive Name | Title | Number of Option Shares |
|---|---|---|
| William Annett | President and Chief Executive Officer | 250,000 |
| Karen Chapman | Vice President of Research | 60,000 |
| Kristine Mechem | Vice President of Marketing | 60,000 |
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements disclaiming any obligation to update future projections. It references risk factors contained in the company's Form 10 filed with the SEC. No specific financial guidance or outlook for the reporting period is provided in this document.
Investor Verification Checklist
- Verify the total number of shares authorized under the Employee Stock Option Plan to assess dilution impact.
- Confirm the vesting schedule details: 25% vests after 12 months of continuous employment, with the remainder vesting in 36 equal monthly installments thereafter.
- Review the company's Form 10 for detailed risk factors referenced in this filing.
- Check subsequent filings for any changes in executive employment status that would affect option exercisability.